Xencor to present Phase 1 results of XmAb819 for advanced kidney cancer at ESMO 2026
Xencor Inc. will disclose Phase 1 data for its bispecific antibody XmAb819, aimed at advanced clear cell renal cell carcinoma, during an oral session at the European Society for Medical Oncology Congress in Madrid on 25 October 2026. The presentation, led by Dr. Sumanta Pal of City of Hope, will cover intravenous dose‑escalation results that are being used to select a dose for a planned Phase 3 trial. Expansion cohorts continue to evaluate IV dosing, while sub‑studies in ENPP3‑positive colorectal, lung and papillary renal cancers opened in Q2 2026 and a post‑immunotherapy cohort opened in Q3 2026. Xencor plans a registration‑enabling study of XmAb819 monotherapy in 2027.
Why it matters
The company says the data will inform dose selection for a pivotal Phase 3 trial, a key step toward potential regulatory approval. Investors should watch for any efficacy or safety signals that could affect Xencor’s valuation and future funding needs.
Key facts
- 1The Phase 1 results will be presented at the ESMO Congress on Sunday, 25 October 2026, 8:30 a.m.–10:00 a.m. CET in Madrid. stocktitan.net
- 2A live webcast of the presentation will be hosted on 26 October 2026 at 7:00 a.m. EDT. investing.com
- 3Dr. Sumanta Pal, Vice Chair of Academic Affairs at City of Hope Comprehensive Cancer Center, will present the data. stocktitan.net
- 4Expansion cohorts are evaluating intravenous doses to support selection of a Phase 3 dose. investing.com
- 5A sub‑study for ENPP3‑positive advanced colorectal cancer, non‑small cell lung cancer and papillary renal cell carcinoma opened to enrollment in Q2 2026. investing.com
- 6A sub‑study for intermediate‑ or poor‑risk advanced ccRCC after first‑line immunotherapy opened in Q3 2026. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.